Prostatype Genomics Stock

Prostatype Genomics Forward P/E

The Forward P/E Ratio of Prostatype Genomics (PROGEN.ST) as of Aug 13, 2026 is -2.26. In the previous year, Forward P/E Ratio was -2.24 — a change of 0.94% (lower).

Forward P/E

-2.26

YoY

0.94%

Last updated:

Forward P/E Ratio of Prostatype Genomics is 2026 -2.26 . Forward P/E Ratio of Prostatype Genomics was 2025 -2.24 . It decreases by 0.94% lower compared to the previous year.
Access this data via the Eulerpool API

Prostatype Genomics Stock analysis

What does Prostatype Genomics do? Prostatype Genomics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Prostatype Genomics stock

Forward P/E Ratio of Prostatype Genomics is -2.26 in 2026.

Forward P/E Ratio of Prostatype Genomics changed from -2.24 to -2.26, representing a 0.94% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Prostatype Genomics since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Prostatype Genomics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Prostatype Genomics

All Key Metrics — Prostatype Genomics